Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 10393 - 10400 of 11621 results
OIG Defines its Priorities in 2014-2018 Strategic Plan
November 25, 2013| Blog| Viewpoint
Treasury Department/IRS Issue Guidance Instructing Employers on How To Make Claims for FICA Refunds or Credits Post-Windsor
November 22, 2013| Blog| Viewpoint
Associational Discrimination Claims under Massachusetts Law Require More than Just Association
November 22, 2013| Blog| Viewpoint
Bill to Ban Pregnancy Discrimination Unanimously Passed by New Jersey Senate
November 22, 2013| Blog| Viewpoint
Treasury Department/IRS Issue Guidance Instructing Employers on How to Make Claims for FICA Refunds or Credits Post-Windsor
November 22, 2013| Advisory| Viewpoint
Google pays BIG to state Attorney Generals for Improper Consumer Tracking
November 22, 2013| Blog| Viewpoint
Want to reduce or suspend safe harbor 401(k) employer contributions mid-year? IRS final regulations provide a new way.
November 20, 2013| Blog| Viewpoint
Career opportunity at a Mintz client!
November 19, 2013| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.